caVos Biotherapeutics

Company Overview

Snapshot

Founded in April 2021 by Yuval Tabach, caVos Biotherapeutics operates with 1-10 employees. The company has raised $3.3M across two funding rounds from six investors. In May 2026, caVos Biotherapeutics was recognized as one of the Most Innovative Life Science Startups at Biomed Israel 2026.

Business overview

caVos Biotherapeutics is a Health Tech & Life Sciences company focused on revolutionizing drug discovery and identification for cancer treatment. The company develops a multi-level genomic algorithm to uncover the genetic basis of extraordinary cancer resistance observed in various animals. By harnessing advanced data and genomics, caVos Biotherapeutics identifies existing anti-cancer mechanisms and novel drug targets, operating within the Pharmaceuticals sector, specifically in Drugs Discovery & Development.

Strategic signal

In May 2026, caVos Biotherapeutics was awarded as one of the Most Innovative Life Science Startups at Biomed Israel 2026. This recognition highlights the company's innovative approach in leveraging genomic algorithms to discover novel anti-cancer drug targets, signaling strong validation of its scientific methodology and potential for future breakthroughs in the pharmaceutical industry.

Company Intelligence Q&A

What is caVos Biotherapeutics' primary focus?

caVos Biotherapeutics is focused on developing novel anti-cancer drugs by uncovering the genetic basis of extraordinary cancer resistance found in various animals, using a multi-level genomic algorithm.

When was caVos Biotherapeutics founded?

caVos Biotherapeutics was founded in April 2021.

Who is a founder of caVos Biotherapeutics?

Yuval Tabach is a founder of caVos Biotherapeutics.

What was a significant recent achievement for caVos Biotherapeutics?

In May 2026, caVos Biotherapeutics was awarded as one of the Most Innovative Life Science Startups at.

Which investors participated in caVos Biotherapeutics' November 2024 funding round?

In November 2024, caVos Biotherapeutics received funding from investors including Entrée Capital and Alumni Ventures.